alacizumab pegol (CDP 791) / UCB - LARVOL DELTA

Daratumumab in Ittp: A Case Series (ASH 2024) - "In relapsed patients, plasma exchange therapy is used, along with capalacizumab and either an increased dose of glucocorticoids or addition of another immunosuppressive therapy (cyclophosphamide, vincristine, cyclosporine, bortezomib, mycophenolate mofetil) (Farzana 2015)...We assessed the clinical and treatment course of two patients at our institution as well as platelet response, duration of response, and patient demographics.Results : Both patients documented in this case series presented with multiply relapsed iTTP after rituximab failure...As treatment with daratumumab becomes more favorable in this context, assessment of the demographic factors and clinical characteristics of patients and their response to the therapy will be important in determining which patient populations should receive daratumumab for treatment of their disease. We plan to conduct a meta-analysis of published literature of daratumumab in the relapse and refractory setting."

Clinical • Amyloidosis • Genetic Disorders • Hematological Disorders • Hematological Malignancies • Immunology • Multiple Myeloma • Obesity • Oncology • Thrombocytopenia • Thrombocytopenic Purpura

DOUBLE TROUBLE: A RARE CASE OF THROMBOTIC THROMBOCYTOPENIC PURPURA AND PANCREATITIS IN THE ICU (CHEST 2024) - "He was also initiated on medical therapy with IV Methylprednisolone and Alacizumab...The patient was discharged in stable condition with a platelet count of 209, oral Prednisone and follow-up with Hematology... Physicians should remember that TTP is a serious hematologic emergency that may present with a wide array of systemic manifestations such as pancreatitis. Physicians should also maintain a high index of suspicion to promptly recognize and treat TTP to prevent mortality while also considering other pathologies that may be presenting concurrently."

Clinical • Anemia • Cardiovascular • Chronic Obstructive Pulmonary Disease • CNS Disorders • Diabetes • Endocrine Disorders • Gastroenterology • Gastrointestinal Disorder • Genetic Disorders • Hematological Disorders • Hepatology • Hypertension • Immunology • Inflammatory Arthritis • Lupus • Nephrology • Pain • Pancreatitis • Respiratory Diseases • Thrombocytopenic Purpura • Thrombosis • HP

[VIRTUAL] A Novel Nanobody: Capalacizumab, in the Modern Era of TTP Treatment (ATS-I 2020) - "As with any novel treatments, further studies are indicated, especially those not funded by the drug manufacturer. Our patient did have a favorable response using capalacizumab in addition to steroids, rituximab, and plasmapheresis."

Cardiovascular • CNS Disorders • Hematological Disorders • Thrombocytopenic Purpura • HP

A Novel Nanobody: Capalacizumab, in the Modern Era of TTP Treatment (ATS 2020) - "As with any novel treatments, further studies are indicated, especially those not funded by the drug manufacturer. Our patient did have a favorable response using capalacizumab in addition to steroids, rituximab, and plasmapheresis."

Cardiovascular • Hematological Disorders • Thrombocytopenia • Thrombocytopenic Purpura • HP